Can [F-18] fluorodeoxyglucose positron emission tomography replace sentinel lymph node biopsy for the detection of axillary metastases in patients with early-stage breast cancer?*

To investigate the value of fluorodeoxyglucose positron emission tomography (FDG-PET) in detecting axillary involvement, and to compare its accuracy with sentinel lymph node biopsy (SLNB) in patients with clinically early-stage breast cancer. Materials and methods: Twenty-eight female patients with histologically-confirmed T1-2 breast cancer who were scheduled to have SLNB were included in the study. FDG-PET images were obtained 1-7 days prior to surgery with an intravenous injection of 370 MBq of FDG, while plasma glucose levels were maintained below 120 mg/dL. All the images were interpreted by 2 independent nuclear medicine specialists, who were blinded to the histological diagnoses. SLNB was performed in standard fashion with peri-tumoral injection of isosulphan blue dye. In all cases, a level I-II axillary dissection was performed following SLNB. Sentinel nodes were processed after formalin fixation; no frozen sections were used. Results: Thirteen (46%) patients were found to have axillary involvement. SLNB (an average of 2.3 LNs removed per patient) demonstrated metastases in all 13 patients. The diagnostic accuracy of FDG-PET was as follows: true-positive in 4 out of 13 patients (overall sensitivity = 31%), false-negative in 1 patient with metastasis (overall specificity = 94%), positive predictive value = 80%, negative predictive value = 63%, and accuracy = 68%. Conclusion: FDG-PET appears to be significantly less accurate than SLNB at detecting axillary metastases. In patients with an axillary-positive PET scan, however, axillary lymph node dissection may be performed without prior SLNB.

Can [F-18] fluorodeoxyglucose positron emission tomography replace sentinel lymph node biopsy for the detection of axillary metastases in patients with early-stage breast cancer?*

To investigate the value of fluorodeoxyglucose positron emission tomography (FDG-PET) in detecting axillary involvement, and to compare its accuracy with sentinel lymph node biopsy (SLNB) in patients with clinically early-stage breast cancer. Materials and methods: Twenty-eight female patients with histologically-confirmed T1-2 breast cancer who were scheduled to have SLNB were included in the study. FDG-PET images were obtained 1-7 days prior to surgery with an intravenous injection of 370 MBq of FDG, while plasma glucose levels were maintained below 120 mg/dL. All the images were interpreted by 2 independent nuclear medicine specialists, who were blinded to the histological diagnoses. SLNB was performed in standard fashion with peri-tumoral injection of isosulphan blue dye. In all cases, a level I-II axillary dissection was performed following SLNB. Sentinel nodes were processed after formalin fixation; no frozen sections were used. Results: Thirteen (46%) patients were found to have axillary involvement. SLNB (an average of 2.3 LNs removed per patient) demonstrated metastases in all 13 patients. The diagnostic accuracy of FDG-PET was as follows: true-positive in 4 out of 13 patients (overall sensitivity = 31%), false-negative in 1 patient with metastasis (overall specificity = 94%), positive predictive value = 80%, negative predictive value = 63%, and accuracy = 68%. Conclusion: FDG-PET appears to be significantly less accurate than SLNB at detecting axillary metastases. In patients with an axillary-positive PET scan, however, axillary lymph node dissection may be performed without prior SLNB.

___

  • Soni NK, Spillane AJ. Experience of sentinel node biopsy alone in early breast cancer without further axillary dissection in patients with negative sentinel node. ANZ J Surg 2005; 75: 292- 9.
  • Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project. Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer 1993; 71(6 Suppl): 2141-50.
  • Spillane AJ, Sacks NP. Role of axillary surgery in early breast cancer: review of the current evidence. Aust N Z J Surg 2000; 70: 515-24. Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer: invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996; 131: 301-8.
  • Lovrics PJ, Chen V, Coates G, Cornacchi SD, Goldsmith CH, Law C et al. A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 2004; 11: 846-53.
  • Haffty BG, Ward B, Pathare P, Salem R, McKhann C, Beinfield M et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997; 15: 691-700.
  • Roumen RM, Kuijt GP, Liem IH, van Beek MW. Treatment of 100 patients with sentinel node-negative breast cancer without further axillary dissection. Br J Surg 2001; 88: 1639-43.
  • Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000; 88: 608-14.
  • Kumar R, Zhuang H, Schnall M, Conant E, Damia S, Weinstein S et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 2006; 27: 231- 6.
  • Zavagno G, De Salvo GL, Scalco G, Boza F, Barutta L, Del Bianco P et al. A Randomized Clinical Trial on Sentinel Lymph Node Biopsy Versus Axillary Lymph Node Dissection in Breast Cancer: Results of the Sentinella/GIVOM Trial. Ann Surg 2008; 247: 207-213.
  • Fehr MK, Hornung R, Varga Z, Burger D, Hess T, Haller U et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004; 10: 89-93.
  • Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2- fluoro-D-glucose PET. Radiology 1993; 187: 743-50.
  • Pietrzyk U, Scheidhauer K, Scharl A, Schuster A, Schicha H. Presurgical visualization of primary breast carcinoma with PET emission and transmission imaging. J Nucl Med 1995; 36: 1882- 4. Scheidhauer K, Scharl A, Pietrzyk U, Wagner R, Göhring UJ, Schomäcker K et al. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996; 23: 618-23.
  • Wahl RL, Kaminski MS, Ethier SP, Hutchins GD. The potential of 2-deoxy-2[18F]fluoro-D-glucose (FDG) for the detection of tumor involvement in lymph nodes. J Nucl Med 1990; 31: 1831- 5. Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R et al. Axillary lymph node staging in breast cancer by 2- fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001; 93: 630-5.
  • Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nüssle K et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28: 351- 8.
  • Zornoza G, Garcia-Velloso MJ, Sola J, Regueira FM, Pina L, Beorlegui C. 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 2004; 30: 15-9.
  • Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23: 1588-93.
  • Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastases: screening with [F-18]2-deoxy- 2-fluoro-D-glucose (FDG) PET. Radiology 1997; 203: 323-7.
  • Crippa F, Agresti R, Seregni E, Greco M, Pascali C, Bogni A et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39: 4-8.
  • Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2- (fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228: 220-7.
  • Barranger E, Grahek D, Antoine M, Montravers F, Talbot JN, Uzan S. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003; 10: 622-7.
  • Wahl RL, Siegel BA, Coleman RE, Gatsonis CG; PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004; 22: 277-85.
  • Guller U, Nitzsche EU, Schirp U, Viehl CT, Torhorst J, Moch H et al. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D- glucose: not yet Breast Cancer Res Treat 2002; 71: 171-3. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007; 18: 473-8.
Turkish Journal of Medical Sciences-Cover
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Sayıdaki Diğer Makaleler

The prognostic value of histological grade in the outcome of patients with invasive breast cancer

Gül DAĞLAR, Yunus Nadi YÜKSEK, Ahmet Uğur GÖZALAN, Tanju TÜTÜNCÜ, Yeşim GÜNGÖR, Nuri Aydın KAMA

Do uroflowmetric findings change by treatment of urinary tract infection in girls with dysfunctional voiding?

Emrah ŞENEL, H. Tuğrul TİRYAKİ, Fatih AKBIYIK, Halil ATAYURT

Acil servise bel ağrısı şikayeti ile başvuran hastalarda oral ve i.m. feniramidolün etkililiği, güvenliliği ve farmakokinetik özellikleri

Hakan ERGÜN, Onur POLAT, N. Arda DEMİRKAN, Müge GÜNALP, Serdar GÜRLER

Familial amyloidosis cutis dyschromica

Ayşe Serap KARADAĞ, Gülçin Güler ŞİMŞEK

Four cases of myotonia congenita in a Turkish family*

Recep AYGÜL, Gökhan ÖZDEMİR, Dilcan KOTAN

Comparative evaluation of the antifungal susceptibility of Candida isolates from blood specimens: results of a study in a tertiary care hospital in Bursa, Turkey

Canan EVCİ, Beyza ENER, Güher GÖRAL, Sevim AKÇAĞLAR

The efficacy, safety, and pharmacokinetics of intramuscular and oral phenyramidol in patients with low back pain in an emergency department

Onur POLAT, Hakan ERGÜN, Müge GÜNALP, N. Arda DEMİRKAN, Serdar GÜRLER

Ali SIZLAN, Uğur GÖKTAŞ, Ceyda ÖZHAN, Mehmet Özgür ÖZHAN, Mehmet Emin ORHAN, Ercan KURT

The relationship between daily caffeine consumption and withdrawal symptoms: a questionnaire-based study

Nermin KÜÇER

Underlying diseases of recurrent pneumonia in Turkish children

Ülker ERTAN, Sinan SARI, Arzıu BAKIRTAŞ, Osman ÖZDEMİR, Pelin ZORLU